Revisiting NTRKs as an emerging oncogene in hematological malignancies

Area of Science:

• Oncology
• Molecular Biology
• Hematology

Background:

• Neurotrophic tyrosine receptor kinase (NTRK) fusions are key drivers in rare solid tumors.
• These fusions, though infrequent, are also detected in common cancers like lung and colorectal carcinomas.
• Current therapies targeting NTRK fusions show significant patient response, primarily in solid tumors.

Purpose of the Study:

• To review the role of NTRK alterations in hematologic malignancies.
• To explore the potential of Trk inhibitors for treating leukemia.
• To contextualize NTRK fusion targeting within the framework of BCR-ABL1 targeting in chronic myeloid leukemia.

Main Methods:

• Literature review of NTRK alterations in hematologic malignancies.
• Analysis of existing data on Trk inhibitor efficacy.
• Comparison with historical targeted therapies in leukemia.

Main Results:

• Deep sequencing reveals NTRK fusions and mutations in various hematologic malignancies.
• Trk inhibitors demonstrate efficacy in preclinical models of NTRK-fusion positive human leukemia cell lines.
• Patient-derived xenograft studies confirm the therapeutic potential of Trk inhibitors in leukemia.

Conclusions:

• NTRK fusions represent a targetable oncogenic driver in a subset of leukemia patients.
• Trk inhibitors hold significant clinical promise for treating specific hematologic malignancies.
• Further investigation into Trk inhibitor utility in leukemia is warranted.